Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib…
Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for…
Read More...
Read More...
